An in vitro Platform of Antigen-Presenting Cells to Evaluate Critical Quality Attributes in Vaccine Formulations
Sanofi-Pasteur is developing new vaccine formulations that need to be evaluated on their efficacy and potency. Traditionally, the use of animal models to predict human immunity has been accepted as the best way to select vaccine formulations. However, animal models can be costly and time-prohibitive, and the assays employed to assess vaccine efficacy and potency are not ideal for rapid screening and optimization of multiple formulations. To overcome these limitations, we propose to test new vaccine formulations utilizing laboratory cultured macrophage cells. Vaccine interactions with macrophages ultimately determine the effectiveness of a given formulation.